Methadone treatment protects against HIV infection : Two decades of experience in the Bronx, New York City.
We undertook a study of the role of methadone maintenance in protecting injecting drug users (IDUs) from human immunodeficiency virus (HIV) infection from the earliest days of the HIV epidemic in New York City to the present.
The historical context of the epidemic in the Bronx is discussed.
For close to two decades, we have been tracking changes in injecting drug use and HIV infection levels in a Bronx cohort study of IDUs.
An initial sample of 622 IDUs was recruited from a methadone treatment program in 1985, with historical data going back to 1978.
Behavioral interviews and HIV testing were performed and methadone treatment program records (urine toxicology and methadone dose history) were reviewed.
We examined both prevalent and incident HIV infections.
The sample included African Americans (24.3%), Latinos (50.3%), and white non-Latinos (24.4%). The average methadone dose was 64 milligrams (mg) per day with an average time in treatment of five and a half years.
We found a very low rate of incident infection of 1.7 per 100 person-years observation since 1986.
Because of this low rate of infection, we were unable to determine the association between methadone treatment factors and HIV seroincidence.
We found that our prevalence data on the 622 IDUs enrolled from 1985 to 1988 yielded strong findings on the role of methadone maintenance in a period when most infections occurred in this population.
HIV seroprevalence was 42.9%. (...)
Mots-clés Pascal : SIDA, Virose, Infection, Toxicomanie, Voie intraveineuse, Méthadone, Analgésique narcotique, Opiacés, Prévention, Facteur risque, Chimiothérapie, Traitement substitutif, Homme, Epidémiologie, New York, Etats Unis, Amérique du Nord, Amérique, Immunopathologie, Immunodéficit
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Drug addiction, Intravenous administration, Methadone, Narcotic analgesic, Opiates, Prevention, Risk factor, Chemotherapy, Replacement therapy, Human, Epidemiology, New York, United States, North America, America, Immunopathology, Immune deficiency
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0414232
Code Inist : 002B05C02D. Création : 22/03/2000.